4,5-Dibenzyl-2,4-dihydro-3H-1,2,4-triazol-3-one | 85562-83-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,5-Dibenzyl-2,4-dihydro-3H-1,2,4-triazol-3-one
• 英文别名: 3,4-dibenzyl-1H-1,2,4-triazol-5-one
• CAS: 85562-83-0
• 化学式: C₁₆H₁₅N₃O
• 分子量: 265.31
• InChiKey: UQSQZZHDKUGQEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
  申请人：G.D. Searle & Co.

  公开号：US20010020100A1

  公开（公告）日：2001-09-06

  A class of N-substituted-1,2,4-triazolone compounds is described for use in treatment of cardiovascular disorders. Compounds of particular interest are angiotensin II antagonists of the formula 1 wherein R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and hydroxyalkyl; wherein R 2 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neo-pentyl, propylthio and butylthio; wherein each of R 3 through R 11 is hydrido with the proviso that at least one of R 5 and R 9 must be selected from COOH, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH, 2 wherein each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.

  描述了一类N-取代-1,2,4-三唑酮化合物，用于治疗心血管疾病。特别感兴趣的化合物是公式1的血管紧张素II拮抗剂，其中R1从甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、4-甲基丁基、正戊基、新戊基、苯基、苄基、苯乙基、环己基、环己基甲基、1-氧乙基、1-氧丙基、1-氧丁基、1-氧戊基和羟基中选择；其中R2从乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、4-甲基丁基、叔丁基、正戊基、新戊基、丙硫基和丁硫基中选择；其中R3至R11中的每一个都是氢，但R5和R9中至少一个必须从COOH、SH、PO3H2、SO3H、CONHNH2、CONHNHSO2CF3、OH中选择；其中R42和R43中的每一个都是独立选择的氯、氰基、硝基、三氟甲基、羟甲酰氧基和三氟甲磺酰基。这些化合物在治疗或控制高血压和充血性心力衰竭方面特别有用。
• 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders
  申请人：G. D. Searle & Co.

  公开号：US20040048911A1

  公开（公告）日：2004-03-11

  A class of 1-phenyl imidazol-2-one biphenylmethyl compounds is described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula 1 wherein each of R 1 , R 2 and R 3 is independently selected from hydrido, alkyl, alkoxy, cyano, halo, hydroxy, carboxyl, alkoxycarbonyl, formyl and acetyl; alkylcarbonyl and haloalkylcarbonyl; with the proviso that at least one of R 1 , R 2 and R 3 must be a substituent other than hydrido, and with the further proviso that when each of R 1 and R 3 is hydrido, then R 2 cannot be chloro; wherein R 4 is hydrido; wherein R 5 is alkyl; and wherein R 6 is tetrazolyl; or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.

  本文描述了一类1-苯基咪唑-2-酮联苯甲基化合物，可用于治疗循环系统疾病。特别感兴趣的化合物是公式1的血管紧张素II拮抗剂，其中R1、R2和R3中的每个基团均独立地选择自氢、烷基、烷氧基、氰基、卤素、羟基、羧基、烷氧羰基、甲酰基和乙酰基；烷基羰基和卤代烷基羰基；但前提是R1、R2和R3中至少有一个基团不是氢基，而且当R1和R3中的每一个基团都是氢基时，R2不能是氯基；其中R4是氢基；R5是烷基；R6是四唑基；或其立体异构体或互变异构体或其药学上可接受的盐。这些化合物在治疗或控制高血压和充血性心力衰竭方面特别有用。
• 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
  申请人：G.D. Searle & Co.

  公开号：EP0504888A1

  公开（公告）日：1992-09-23

  A class of 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds is described for use in treatment of circulatory disorders such as hypertension. Compounds of particular interest are angiotensin II antagonists of the formula wherein A is selected from wherein m is one; wherein R¹ is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, benzyl, cyclohexyl, cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neo-pentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxypentyl, halo, difluoromethyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, 1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio: wherein each of R³, R⁴, R⁶ through R¹¹ is hydrido and R⁵ is selected from COOH, SH, PO₃H2, SO₃H, CONHNH2, CONHNHSO₂CF₃, OH, wherein each of R⁴² and R⁴³ is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl.

  描述了一类 5-芳基杂芳基烷基-1,3,5-三取代-1,2,4-三唑化合物，用于治疗高血压等循环系统疾病。特别感兴趣的化合物是式中的血管紧张素 II 拮抗剂 其中 A 选自 其中m为1； 其中R¹选自乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、4-甲基丁基、正戊基、新戊基、苄基、环己基、环己基甲基、2-丁烯基、3-丁烯基、2-丁炔基、3-丁炔基和2-羟基丁基；其中 R² 选自乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、4-甲基丁基、 叔丁基、正戊基、新戊基、1-氧代乙基、1-氧代丙基、1-氧代丁基1-氧代戊基、1,1-二甲氧基丙基、1,1-二甲氧基戊基、卤代、二氟甲基、1-氧代-2-苯基乙基、1-氧代-2-环己基乙基、1,1-二氟-2-苯基乙基、1,1-二氟-2-环己基乙基、2-环己基乙基，1,1-二氟-3-环己基丙基，1,1-二甲氧基丁基，1,1-二氟乙基，1,1-二氟丙基，1,1-二氟丁基，1,1-二氟戊基，苄基、2-苯基乙基、1,1-二氟-3-苯基丙基、环己基甲基、环己基甲酰基、1-丁烯基、2-丁烯基、3-丁烯基、1-丁炔基、2-丁炔基、3-丁炔基、丙硫基和丁硫基：其中 R³、R⁴、R⁶ 至 R¹¹ 中的每一个均为氢基，而 R⁵ 选自 COOH、SH、PO₃H2、SO₃H、CONHNH2、CONHNHSO₂CF₃、OH、 其中每个 R⁴² 和 R⁴³ 独立选自氯、氰基、硝基、三氟甲基、甲氧羰基和三氟甲基磺酰基。
• N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
  申请人：G.D. Searle & Co.

  公开号：EP0508393A1

  公开（公告）日：1992-10-14

  A class of N-arylheteroarylalkyl imidazol-2-one compounds is described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Compounds of particular interest are angiotensin II antagonists of the formula wherein A is selected from wherein m is one; wherein R¹ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, 2-ethylbutyl, n-pentyl, neopentyl, phenyl, methylphenyl, difluorophenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R⁰ is hydrido; wherein R² is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R³, R⁴, R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹ is hydrido and R⁵ must be selected from COOH, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH, wherein each of R⁴² and R⁴³ is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-aceptable salt thereof.

  描述了一类 N-芳基杂芳基烷基咪唑-2-酮化合物，用于治疗高血压和充血性心力衰竭等循环系统疾病。特别感兴趣的化合物是式中的血管紧张素 II 拮抗剂 其中 A 选自 其中 m 为 1； 其中R¹选自甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、4-甲基丁基、2-乙基丁基、正戊基、新戊基、苯基、甲基苯基、二氟苯基苄基、苯乙基、环己基、环己基甲基、环己基乙基、环己基甲酰基、1-氧代-2-环己基乙基、苯甲酰基、1-氧代-2-苯乙基、1-氧代丙基、1-氧代丁基、1-氧代戊基和 2-羟基丁基；其中 R⁰为氢基；其中 R² 选自甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、正戊基、异戊基、新戊基、苯基、苄基、苯乙基、环己基、环己基甲基、丙硫基、丁硫基和羟烷基；其中 R³、R⁴、R⁶、R⁷、R⁸、R⁹、R¹⁰ 和 R¹¹ 中的每一个都是氢基，而 R⁵ 必须选自 COOH、SH、PO₃H₂、SO₃H、CONHNH₂、CONHNHSO₂CF₃、OH、 其中 R⁴² 和 R⁴³ 各自独立地选自氯、氰基、硝基、三氟甲基、甲氧羰基和三氟甲基磺酰基；或其同系物或其可药用盐。
• 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists
  申请人：G.D. SEARLE & CO.

  公开号：EP0978515A2

  公开（公告）日：2000-02-09

  A class of 1-phenyl imidazol-2-one biphenylmethyl compounds is described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula wherein each of R1, R2 and R3 is independently selected from hydrogen, alkyl, alkoxy, cyano, halo, hydroxy, nitro, amino, alkylamino,carboxyl, alkoxycarbonyl, formyl, alkylcarbonyl and haloalkylcarbonyl; with the proviso that at least one of R1, R2 and R3 must be a substituent other than hydrogen, and with the further proviso that when each of R1 and R3 is hydrogen, then R2 cannot be chloro; wherein R4 is selected from hydrogen, alkyl, halo, haloalkyl, formyl, carboxyl and alkoxyalkyl; wherein R5 is selected from alkyl, phenyl, phenylalkyl, cycloalkyl and cycloalkylalkyl; and wherein R6 is an acidic group selected from COOH and or a stereoisomer or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.

  描述了一类用于治疗循环系统疾病的 1-苯基咪唑-2-酮联苯甲基化合物。特别感兴趣的化合物是式中的血管紧张素 II 拮抗剂 其中 R1、R2 和 R3 各自独立地选自氢、烷基、烷氧基、氰基、卤代、羟基、硝基、氨基、烷基氨基、羧基、烷氧羰基、甲酰基、烷基羰基和卤代烷基羰基；但 R1、R2 和 R3 中至少有一个必须是除氢以外的取代基，而且当 R1 和 R3 都是氢时，R2 不能是氯；其中 R4 选自氢、烷基、卤代、卤代烷基、甲酰基、羧基和烷氧基烷基； 其中 R5 选自烷基、苯基、苯基烷基、环烷基和环烷基烷基；以及其中 R6 是选自 COOH 和 或其立体异构体或同系物或其药学上可接受的盐。 这些化合物尤其适用于治疗或控制高血压和充血性心力衰竭。